Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

Lawn, Stephen D., Mwaba, Peter, Bates, Matthew, Piatek, Amy, Alexander, Heather, Marais, Ben J., Cuevas, Luis E., McHugh, Timothy D., Zijenah, Lynn, Kapata, Nathan, Abubakar, Ibrahim, McNerney, Ruth, Hoelscher, Michael, Memish, Ziad A., Migliori, Giovanni Battista, Kim, Peter, Maeurer, Markus, Schito, Marco and Zumla, Alimuddin (2013) Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infec tious Diseases, 13 (4). pp. 349-361. ISSN 1473-3099

Documents
Lawn Xpert LID 2013.pdf

Request a copy
[img] PDF
Lawn Xpert LID 2013.pdf - Whole Document
Restricted to Repository staff only

199kB
Item Type:Article
Item Status:Live Archive

Abstract

Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010. This assay was specifically recommended for use as the initial diagnostic test for suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of countries with a high tuberculosis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated the assay into their national tuberculosis programme guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review the rapidly growing body of scientific literature and discuss the advantages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics pipeline should remain a major priority for funders and researchers.

Keywords:Xpert, Tuberculosis, mycobacterium, diagnostics
Subjects:A Medicine and Dentistry > A300 Clinical Medicine
Divisions:College of Science > School of Life Sciences
Related URLs:
ID Code:28388
Deposited On:10 Oct 2017 19:59

Repository Staff Only: item control page